###begin article-title 0
Poly(ADP-ribose) polymerase (PARP-1) and p53 independently function in regulating double-strand break repair in primate cells
###end article-title 0
###begin p 1
###xml 99 134 99 134 <email xmlns:xlink="http://www.w3.org/1999/xlink">lisa.wiesmueller@medizin.uni-ulm.de</email>
To whom correspondence should be addressed. Tel: +49 731 500 27640; Fax: +49 731 500 26674; Email: lisa.wiesmueller@medizin.uni-ulm.de
###end p 1
###begin p 2
PARP-1 is rapidly activated by DNA strand breaks, which finally leads to the modulation of multiple protein activities in DNA replication, DNA repair and checkpoint control. PARP-1 may be involved in homologous recombination, and poly(ADP-ribosyl)ation of p53 represents one possible mechanism that activates p53 as a recombination surveillance factor. Here, we examined the influence of PARP-1 on homology-directed double-strand break (DSB) repair by use of a fluorescence- and I-SceI- meganuclease-based assay with either episomal or chromosomally integrated DNA substrates. Surprisingly, the transient expression of both full-length PARP-1 and of a dominant negative mutant, retaining the DNA-binding but lacking the catalytic domain, down-regulated DSB repair in a dose-dependent manner. This effect was seen regardless of p53 status, however, with enhanced inhibition in the presence of wild-type p53. Taken together, our data reveal that PARP-1 overexpression counteracts DSB repair independently of its enzymatic activity and of poly(ADP-ribosyl)ation of p53 in particular, but synergizes with p53 in suppressing chromosomal rearrangements.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 245 246 245 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c1">1</xref>
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c2">2</xref>
###xml 752 753 752 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c3">3</xref>
###xml 1042 1047 1042 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rad51</italic>
###xml 1049 1054 1049 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rad50</italic>
###xml 1058 1062 1058 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nbs1</italic>
###xml 1064 1065 1064 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c4">4</xref>
###xml 1066 1067 1066 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c7">7</xref>
###xml 1009 1013 <span type="species:ncbi:10090">mice</span>
Double-strand breaks (DSBs) represent the most detrimental DNA lesion and may be formed by ionizing radiation, oxygen radicals, inhibition of topoisomerase or DNA polymerase activity, or by specific endonucleases, such as the V(D)J recombinase (1,2). Error-prone DSB repair may lead to cancer-inducing genetic aberrations, including translocations, deletions, chromosome losses or gene amplification. Mammalian cells utilize two major DSB repair pathways, namely the mutagenic mechanism of non-homologous end joining (NHEJ) and the generally nonmutagenic process of homologous recombination (HR). Conservative HR, i.e. gene conversion or cross-over, depends on the strand transfer activity of Rad51 and auxiliary proteins of the Rad52 epistasis group (3). Nonconservative HR, i.e. single-strand annealing (SSA) or replication slippage, represents a Rad51-independent mechanism. The critical importance of HR for mammalian organisms was convincingly demonstrated by the embryonic lethal phenotypes of knockout mice with deficiencies in either Rad51, Rad50 or Nbs1 (4-7).
###end p 4
###begin p 5
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c8">8</xref>
###xml 381 382 381 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c9">9</xref>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c10">10</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c11">11</xref>
###xml 661 667 661 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARP-1</italic>
###xml 846 848 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c12">12</xref>
###xml 849 851 849 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c15">15</xref>
###xml 903 905 903 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c16">16</xref>
###xml 906 908 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c17">17</xref>
###xml 1184 1186 1184 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c18">18</xref>
###xml 1187 1189 1187 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c19">19</xref>
###xml 1427 1429 1427 1429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c20">20</xref>
###xml 1576 1578 1576 1578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c21">21</xref>
###xml 1579 1581 1579 1581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c22">22</xref>
###xml 1777 1779 1777 1779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c23">23</xref>
###xml 1902 1907 1902 1907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 1910 1912 1910 1912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c20">20</xref>
###xml 691 695 <span type="species:ncbi:10090">mice</span>
###xml 1598 1603 <span type="species:ncbi:10090">mouse</span>
###xml 2016 2031 <span type="species:ncbi:10029">Chinese hamster</span>
Activation of PARP-1 and p53 represents two of the earliest DNA damage responses that trigger various cellular functions involved in the maintenance of the genome stability (8). PARP-1 binds to DNA strand breaks with high affinity and subsequently poly(ADP-ribosyl)ates itself and other nuclear proteins involved in chromatin structure, DNA base excision repair and recombination (9,10). Automodification of PARP-1, which entails a massive increase in negative charges, may lead to the dissociation of PARP-1 from the strand break and thus give access to DNA repair enzymes in a controlled manner (11). In agreement with an involvement of PARP-1 in DSB repair, PARP-1 disruption in knockout mice or inhibition of poly(ADP-ribosyl)ation in cellular systems stimulate micronucleus formation, sister-chromatid exchange (SCE) and gene amplification (12-15). HR participates in SCEs and gene amplifications (16,17), suggesting an involvement of PARP-1 in HR. Moreover, PARP-1 was reported to co-immunoprecipitate with the Werner syndrome (WRN) protein, a RecQ helicase that suppresses error-prone Rad51-dependent recombination by branch migrating illegitimate recombination intermediates (18,19). However, recent observations indicated that PARP-1 is not required for the assembly of Rad51 foci in the nucleus and does not colocalize with Rad51, indicating that PARP-1 does not represent a component of the recombination machinery (20). So far, the results from recombination measurements have not provided a conclusive picture of the role of PARP-1 in HR. Waldman and colleagues (21,22) showed that in mouse fibroblasts, a competitive inhibitor of poly(ADP-ribosyl)ation does not affect extrachromosomal HR but stimulates intrachromosomal HR. In contrast, Semionov and colleagues (23) noticed that chemical inhibition of PARP-1 in the same cell type positively regulates extrachromosomal HR, while Schultz et al. (20) were unable to see any changes in HR frequencies with chromosomally integrated substrates, when using Chinese hamster cells.
###end p 5
###begin p 6
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c24">24</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c32">32</xref>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c10">10</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c33">33</xref>
###xml 754 756 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c34">34</xref>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
###xml 1046 1048 1046 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c33">33</xref>
###xml 1049 1051 1049 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c34">34</xref>
###xml 1052 1054 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
###xml 1055 1057 1055 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c39">39</xref>
###xml 1506 1508 1506 1508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c40">40</xref>
PARP-1 was proposed to act upstream of p53 in the damage signalling pathway, either via physical interactions with and poly(ADP-ribosyl)ation of p53 or, indirectly, via stimulation of the DNA strand break sensing ATM kinase which phosphorylates p53 on serine 15 (24-32). Moreover, PARP-1 and p53 were demonstrated to cooperate in stabilizing the genome (10), suggesting a functional connection in DNA repair. In addition to a role of p53 in checkpoint control, numerous studies showed a close association between p53 and DNA repair (33). In particular, compelling evidence indicates that wild-type p53 (wt-p53) down-regulates spontaneous and DSB-induced HR, independently of its role in transcriptional transactivation, cell cycle control and apoptosis (34-37). Concerning the mechanism by which p53 directly counteracts HR, important clues have come from the identification of p53-Rad51 complexes, the characterization of the physical interactions between p53 and strand exchange intermediates, and from studies on the DNA substrate dependence (33,34,37-39). From these results, it is conceivable that p53 abrogates continued strand exchange by the recombinase Rad51 after specifically recognizing erroneous intermediates of HR. Phosphorylation by ATM and the interaction with Bloom's syndrome (BLM) protein, another RecQ DNA helicase which may counteract defective processing of DNA replication intermediates, seem to be important in stabilizing p53 contacts in the vicinity of the DSB repair machinery (40).
###end p 6
###begin p 7
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c20">20</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c23">23</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
###xml 624 631 624 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 633 635 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
###xml 833 835 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c41">41</xref>
###xml 836 838 836 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c43">43</xref>
In the present work, we evaluated the precise role of PARP-1 in homology-directed DSB repair. Previous studies utilized recombination assay systems that rely on colony outgrowth under drug selection, but conflicting data were obtained (20-23). Here, we applied our fluorescence-based DSB repair assay that scores the fraction of EGFP-positive cells in a population of nonfluorescent cells (37). To discriminate between PARP-1 functions in recombinative versus alternative DNA repair pathways, we applied a test system which has been designed in such a way as to trigger recombinative DNA exchange processes by DSB formation in vivo (37). Trans-dominant inhibition of poly(ADP- ribosyl)ation by overexpressing the DNA-binding domain of PARP-1 (PARP-DBD) has previously been exploited as a powerful tool to examine the role of PARP-1 (41-43). We therefore compared the consequences of ectopically expressing PARP-DBD and PARP-1 on HR within extra- or intrachromosomal DNA substrates. To understand whether recombination regulation by PARP-1 involves direct protein-protein interactions or poly(ADP-ribosyl)ation of p53, we extended our studies on DSB repair to cellular systems with differing p53 status.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Plasmid constructs
###end title 9
###begin p 10
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c44">44</xref>
pGC-PARP-DBD and pGC-PARP-1 were created by transferring the SmaI fragment, encompassing the region of cDNA encoding truncated and full-length PARP-1, from the vector pPARP6 and pPARP31, respectively, into the EcoRV- restriction site of pGC (44). DNA-modifying enzymes were purchased from Roche and New England Biolabs.
###end p 10
###begin title 11
###xml 45 58 <span type="species:ncbi:9544">rhesus monkey</span>
Cell culture and establishment of transgenic rhesus monkey cell lines
###end title 11
###begin p 12
###xml 30 31 30 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 52 66 52 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Macaca mulatta</italic>
###xml 168 169 168 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 387 389 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c38">38</xref>
###xml 439 441 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
###xml 37 50 <span type="species:ncbi:9544">rhesus monkey</span>
###xml 52 66 <span type="species:ncbi:9544">Macaca mulatta</span>
###xml 83 88 <span type="species:ncbi:9606">human</span>
The parental lines were LLC-MK2 from rhesus monkey (Macaca mulatta) kidney and the human chronic myelogenous leukaemia cell line K562. Concerning the p53 status, LLC-MK2 cells endogenously express p53(Delta237-239), which displays a Pab240 reactive conformation, and is inactive with regards to transcriptional transactivation, cell cycle control or recombination regulatory activities (38). In K562, the p53 gene is homozygously deleted (37).
###end p 12
###begin p 13
###xml 6 7 6 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 20 21 20 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 296 297 290 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 299 301 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c35">35</xref>
###xml 302 304 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c38">38</xref>
###xml 461 463 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c45">45</xref>
###xml 486 488 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c35">35</xref>
###xml 31 34 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 307 310 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 317 320 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 332 335 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 396 399 <span type="species:ncbi:12202?0.5">LMV</span>
LLC-MK2(neo), LLC-MK2(p53her), LMV and newly established transgenic clones were maintained at 37degreesC in DMEM supplemented with 10% FCS. FCS had been stripped by stirring 1 litre with 10 g charcoal (Norit A, Merck) and 1 g Dextran 40 (Merck) for 30 min and subsequent centrifugation at 13 000 g (35,38). LMV-PARP, LMV-p53her and LMV-p53her/PARP cells were established after co-transfection of LMV cells with pGC-PARP-1 (8 microg) and/or pSV53her (8 microg) (45) and phyg (2 microg) (35). Antibiotic selection was performed by the addition of 0.2 mg/ml hygromycin B (Roche). Six to 12 hygromycin-resistant clones were analysed each for PARP-1 and/or p53her expression by western analysis of total homogenates.
###end p 13
###begin p 14
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
Clones derived from K562 cells were maintained in phenol red-free RPMI with 12% charcoal-stripped FCS (37). K562 cells expressing the transcription factor Gal4ERVP (KMV) were utilized for estradiol-inducible expression of I-SceI meganuclease in transient electroporation assays. KMV subclones with stably integrated HR-EGFP/3'EGFP recombination plasmid and KMV(p53her) cells with HR-EGFP/3'EGFP were subjected to the analysis of DSB repair on cellular chromosomes.
###end p 14
###begin p 15
###xml 51 61 51 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mycoplasma</italic>
The cell cultures used in this work were free from Mycoplasma contamination.
###end p 15
###begin title 16
Cell cycle analysis and detection of apoptosis by fluorescence microscopy
###end title 16
###begin p 17
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c46">46</xref>
###xml 445 447 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c35">35</xref>
Cell cycle profiles were determined after preparation of cells essentially as described (46). Briefly, log-phase cells were transferred to medium containing 1 microM beta-estradiol (Sigma). Twenty-four, 48 and 72 h later, the cells were collected by trypsinization and centrifugation, fixed, stained with propidium iodide and analysed in a FACS(R) Calibur flow cytometer (Becton Dickinson). Generation times were determined as described before (35).
###end p 17
###begin p 18
###xml 238 241 227 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">137</sup>
###xml 619 620 604 605 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
For fluorescence microscopy, cells were grown overnight on coverslips in six-well plates followed by addition of 1 microM beta-estradiol to the medium and incubation for 4 h. Subsequently, the cells were gamma-irradiated with 5 Gy from a 137Cs source. After further incubation for 12 h in fresh culture medium, the slides were washed with PBS and fixed with 3.7% formaldehyde in PBS for 10 min at room temperature. Fixed slides were permeabilized with 0.3% Triton X-100 for 3 min. The preparations were stained with 0.1 microg/ml 4',6-diamidino-2-phenylindole (DAPI) in PBS for 10 min in the dark, washed with PBS and H2O, and then mounted. Images were taken with a Leica epifluorescence microscope equipped with objective lenses 63x/1.4 and 40x/1.0 and a digital camera (Spot Model 1.3.0).
###end p 18
###begin title 19
Immunoblot analysis
###end title 19
###begin p 20
###xml 356 357 352 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 669 670 652 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 889 894 <span type="species:ncbi:9606">human</span>
###xml 942 947 <span type="species:ncbi:9940">sheep</span>
###xml 969 974 <span type="species:ncbi:9606">human</span>
###xml 1092 1096 <span type="species:ncbi:9925">goat</span>
###xml 1181 1186 <span type="species:ncbi:9606">human</span>
###xml 1305 1309 <span type="species:ncbi:9925">goat</span>
For western blotting, monkey cells were either left untreated or incubated with estradiol and/or transfected with expression plasmids. gamma-Irradiation was performed as above. At the times indicated, the cells were harvested, washed with PBS and total cell homogenates obtained by scraping the cells from the culture dish with a rubber policeman; 1-2 x 106 cells were resuspended in 100 microl 3x SDS sample buffer (65 mM Tris-HCl, pH 6.8; 10% glycerol; 2.3% SDS; 5% beta-mercaptoethanol; bromophenol blue) and incubated at 99degreesC for 8 min. K562-derived cells were harvested by centrifugation and processed as described for monkey cells. Homogenates from 2-3 x 105 cells were electrophoresed on 8-15% PAGE and transferred to Immobilon-P membranes (Millipore). Proteins were immunodetected by the following primary antibodies: DO1 directed against the N-terminal amino acids 21-25 of human p53 (Oncogene/Calbiochem), the IgG fraction of sheep serum raised against human p53 (Roche Diagnostics), mAb F-I-23 directed against the DNA binding domain of PARP-1 (kind gift of G.G. Poirier) or goat polyclonal IgG N-20 raised against the PARP-1 N-terminus (Santa Cruz), Ab-1 against human p21 (Oncogene/Calbiochem) and 2D2 against Bax (Biocarta). For western analyses of actin, we applied affinity-purified goat polyclonal antibody I-19 (Santa Cruz), for alpha- and beta-tubulin mAbs DM1A+DM1B (Biocarta). Affinity purified, peroxidase-conjugated secondary IgGs were obtained from Biomol. Visualization of the immunocomplexed bands was achieved by Super-Signal West Dura Extended Duration Substrate chemiluminescence enhancement (Pierce).
###end p 20
###begin title 21
Recombination assays
###end title 21
###begin p 22
###xml 82 83 82 83 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 96 97 96 97 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 107 110 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 112 115 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 124 127 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 137 140 <span type="species:ncbi:12202?0.5">LMV</span>
For the determination of recombination frequencies with plasmid substrates, LLC-MK2(neo), LLC-MK2(p53her), LMV, LMV-p53her, LMV-PARP and LMV-p53her/PARP cells were grown overnight in six-well plates, thereby reaching 50-80% confluency. The cells were then subjected to lipofection with a total amount of 2 microg plasmid DNA [recombination plasmid, I-SceI expression vector pCMV-I-SceI, and PARP expression or pBlue Script II KS (+/-) (pBs) control plasmid] and 4 microl FUGENE 6 Transfection Reagent according to the manufacturer's instructions (Roche). Subsequently, transfected cultures were incubated in the presence of 1 microM estradiol until FACS(R) analysis. Poly(ADP-ribosyl)ation was inhibited by the inclusion of 1 mM 3-aminobenzamide (Sigma), caspase-mediated cleavage was antagonized by the caspase inhibitor Z-DEVD-FMK (Sigma) at a concentration of 50 microM for 24 h, followed by flow cytometric quantification of recombination frequencies 48 h after removal of Z-DEVD-FMK.
###end p 22
###begin p 23
###xml 101 102 101 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
For the determination of recombination frequencies with chromosomally integrated substrates, 0.4 x 107 KMV or KMV(p53her) cells, carrying chromosomally integrated HR-EGFP/3'EGFP plasmid, were electroporated at 240 V and 1050 mF with a total amount of 20 microg plasmid DNA (pCMV-I-SceI and PARP expression plasmid or pBS) and subsequently cultivated in fresh tissue culture medium with 200 nM beta-estradiol.
###end p 23
###begin p 24
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 193 194 193 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 234 238 234 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 455 457 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
###xml 565 569 563 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
For recombination measurements 48-72 h after transfection, 0.1-1 x 107 cells were harvested, washed in 1-5 ml PBS supplemented with 0.2% EDTA (PBS-EDTA) and resuspended at a density of 2-5 x 106 cells/ml in PBS-EDTA. To determine the EGFP reconstitution frequency from the fraction of green fluorescent cells within a population of nonfluorescent cells, the cells were analysed flow-cytometrically in a FACS(R) (Becton Dickinson) as described previously (37). Each measurement was paralleled by the same cotransfection including a control plasmid, which carried wt-EGFP at the acceptor position. The fraction of EGFP-positive cells in these controls was determined and was used to normalize each single recombination frequency, to exclude rate deviations related to growth regulatory effects. Each experiment was carried out at least two times with one to three independent measurements for each cell clone or transfection set-up, to calculate mean values and SEM.
###end p 24
###begin title 25
RESULTS
###end title 25
###begin title 26
PARP-1 down-regulates DSB repair independently of its poly(ADP-ribosyl)ation activity
###end title 26
###begin p 27
###xml 51 57 51 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARP-1</italic>
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c12">12</xref>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c15">15</xref>
###xml 216 221 216 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c20">20</xref>
PARP-1 has been linked to DNA recombination, since PARP-1 gene disruption or inhibition of poly(ADP-ribosyl)ation stimulate SCE and gene amplification (12-15). However, from their chemical inhibitor studies, Schultz et al. concluded that poly(ADP-ribosyl)ation does not play an important role in homology-directed DSB-repair (20).
###end p 27
###begin p 28
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 305 309 305 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
###xml 578 582 578 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 597 604 597 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EJ-EGFP</italic>
###xml 606 613 606 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HR-EGFP</italic>
###xml 623 627 619 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 634 635 630 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f1">1</xref>
###xml 704 708 700 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 719 720 715 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 721 725 717 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 812 816 808 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 1297 1301 1293 1297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
To clarify the role of PARP-1 in HR, we modulated PARP-1 function by ectopically expressing either full-length PARP-1 or the mere DNA binding domain (DBD), which leads to trans-dominant inhibition of poly(ADP-ribosyl)ation, followed by quantitative analysis of homology-directed DSB repair. We applied an EGFP-based assay, in which recombinative DNA-exchange processes are triggered by targeted DSB formation in living cells (37). When the rare-cutting meganuclease I-SceI is expressed, it will cleave the recombination substrate at the recognition sequence within the acceptor EGFP gene variant (EJ-EGFP, HR-EGFP or Delta-EGFP; Fig. 1A). Subsequently, HR between the acceptor and the 5' truncated donor EGFP sequence (3'EGFP), located downstream on the same or on the sister chromatid, may restore a functional EGFP gene. Accordingly, gene conversion, cross-over, SSA and replication slippage may all give rise to a population of green fluorescent cells. To quantify recombination frequencies, the ratios between green fluorescent cells and the total number of cells in the population was determined by flow cytometry. In order to exclude rate deviations caused by growth regulatory effects with the individual cell type used, a cotransfection with a control plasmid carrying a wild-type copy of EGFP at the acceptor position was performed in parallel with each recombination experiment and was used to normalize recombination frequency.
###end p 28
###begin p 29
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c38">38</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c41">41</xref>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c47">47</xref>
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f1">1</xref>
###xml 519 521 513 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;2</sup>
###xml 529 530 523 524 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 670 671 664 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f1">1</xref>
To study HR as a function of PARP-1 activity, we transfected LLC-MK2(neo) cells (38) with plasmids pPARP6 or pPARP31 (41,47). These plasmids direct the overexpression of PARP-DBD and PARP-1, respectively, as was confirmed by western blotting (Fig. 1C). The recombination vector Delta-EGFP/3'EGFP as well as the expression construct for I-SceI meganuclease were introduced concomitantly and FACS(R) analysis was performed 72 h later. The absolute recombination frequency for the pBS-transfected control cells was 29 x 10-2. LLC-MK2(neo) cells ectopically expressing PARP-DBD or PARP-1 showed recombination frequencies that were reduced by 42% and 19%, respectively (Fig. 1B).
###end p 29
###begin p 30
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c25">25</xref>
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c26">26</xref>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c34">34</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c38">38</xref>
###xml 245 246 245 246 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 343 344 339 340 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 354 356 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c38">38</xref>
###xml 365 366 361 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 393 394 389 390 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 607 609 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c38">38</xref>
###xml 610 612 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c45">45</xref>
###xml 678 682 674 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 741 742 737 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f1">1</xref>
###xml 770 771 766 767 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 879 880 875 876 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 435 440 <span type="species:ncbi:9606">human</span>
###xml 461 466 <span type="species:ncbi:9606">human</span>
Previous reports indicated that PARP-1 poly(ADP-ribosyl)ates p53 (25,26), another recombination-regulatory molecule (34-38). To investigate the consequences of a change in the PARP-1 activity status in a wt-p53 background, we replaced the LLC-MK2(neo) line, endogenously expressing the functionally inactive mutant p53(Delta237-239), by LLC-MK2(p53her) (38). LLC-MK2(p53her) cells are a LLC-MK2(neo) derivative expressing p53her, i.e. human wt-p53 fused to the human estrogen receptor hormone-binding domain, which represents bona fide wt-p53 in the presence of estradiol as verified by functional studies (38,45). p53her expression resulted in a 49% decrease in HR measured by EGFP reconstitution among successfully transfected cells (Fig. 1B). When we subjected LLC-MK2(p53her) cells to cotransfections with pPARP6 or pPARP31, we monitored a 58% and 55% reduction in the LLC-MK2(neo) control recombination frequency due to the combined expression of exogenous p53her/PARP-DBD and p53her/PARP-1 proteins, respectively.
###end p 30
###begin p 31
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c9">9</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c10">10</xref>
###xml 247 248 247 248 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 357 358 355 356 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
To examine the DSB repair phenotype of cells after chemical inhibition of PARP-1 enzyme activity, we determined the effect of the poly(ADP-ribosyl)ation inhibitor, 3-aminobenzamide (3-AB) (reviewed in 9,10). After a 24 h treatment with 3-AB LLC-MK2(neo) cells exhibited DNA exchange frequencies that were decreased by 16 +/- 5%, PARP-1 overexpressing LLC-MK2(neo) cells showed a 28 +/- 9% reduction due to drug treatment, i.e. both overexpression of the trans-dominant-negative PARP-DBD and enzymatic inactivation of PARP-1 caused down-regulation of HR. Taken together, in our experiments with an extrachromosomal recombination plasmid, suppression of HR by PARP-1 did not depend on its enzymatic activity.
###end p 31
###begin title 32
Overexpression of either PARP-DBD or PARP-1 suppress HR between chromosomally integrated DNA substrates
###end title 32
###begin p 33
###xml 138 139 138 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c9">9</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
###xml 532 533 532 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f1">1</xref>
###xml 757 761 757 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
PARP-1 has been shown to poly(ADP-ribosyl)ate several architectural components of the eukaryotic chromatin including histones H1 and H2B (9). To ask the question whether chromatin packaging of the DNA exchange substrates may influence the regulatory effect of PARP-1 on DSB repair, we chose to modify the PARP-1 activity status in cell lines carrying recombination substrates in the cellular chromosomes. For that purpose, we utilized K562-derived KMV cell clones, which carry a stably integrated HR-EGFP/3'EGFP substrate (37; Fig. 1A). In our previous study, we demonstrated by genomic PCR analyses of the recombination products from the chromosomes of sorted green fluorescing cells that green fluorescence indeed resulted from the reconstitution of a wt-EGFP gene by homology-directed DSB repair.
###end p 33
###begin p 34
###xml 350 352 350 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;4</sup>
###xml 510 511 510 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f2">2</xref>
###xml 750 751 750 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f2">2</xref>
###xml 893 895 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
###xml 902 903 890 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f2">2</xref>
###xml 1048 1049 1036 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f2">2</xref>
###xml 1244 1246 1232 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
###xml 1281 1288 1269 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HR-EGFP</italic>
###xml 1293 1294 1281 1282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 1295 1299 1283 1287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
To introduce a DSB at the position of the I-SceI recognition sequence within the chromosome, we electroporated the tester strain with the I-SceI expression plasmid pCMV-I-SceI. To alter PARP-1 activities, we simultaneously introduced either pPARP6 or pPARP31. In control experiments with pBS, we recorded an absolute recombination frequency of 8 x 10-4 for the p53-negative KMV line. Strikingly, almost complete recombination suppression was caused by the ectopic expression of either PARP-DBD or PARP-1 (Fig. 2A). To be able to detect cooperativity between PARP-1 and p53 in the combined analysis, expression constructs for low-level expression were purposefully chosen such that only small effects were achieved with PARP-DBD or PARP-1 alone (Fig. 2B). For that purpose we utilized the pGC-vector, which produces approximately100-fold lower protein amounts as compared with the pCMV-vector (37; Fig. 2C). Consequently, no significant recombination suppression was noted in KMV cells upon transfection with either pGC-PARP-DBD or pGC-PARP-1 (Fig. 2B). To examine the effect of p53, we utilized KMV cells stably transfected with both the HR-EGFP/3'EGFP recombination plasmid and with pSV53her, the latter providing stable expression of p53her (37). In KMV(p53her) cells HR between HR-EGFP and 3'EGFP was reduced by 58%, as compared with the KMV control. In contrast to the situation in KMV cells, transfection of KMV(p53her) cells with either pGC-PARP-DBD or pGC-PARP-1 caused a dramatic decrease in the recombination frequencies down to background values. In conclusion, recombination interference by PARP-DBD and PARP-1 became apparent both with DNA substrates that were presented on transiently transfected plasmid DNA and on the chromosome and was dose-dependent.
###end p 34
###begin title 35
Biological consequences of PARP-1 expression in stably transfected cells
###end title 35
###begin p 36
###xml 208 209 208 209 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c35">35</xref>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
###xml 1247 1248 1247 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f3">3</xref>
###xml 1566 1567 1566 1567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f3">3</xref>
###xml 192 195 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 409 413 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 647 650 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1133 1136 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1145 1148 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1214 1217 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1224 1227 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1254 1257 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1269 1272 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1571 1574 <span type="species:ncbi:12202?0.5">LMV</span>
So far, our data from transient expression studies demonstrated that PARP-1 inhibits DSB repair. Next, we generated stable cell clones inducibly expressing PARP-1. As a parental line we chose LMV, i.e. LLC-MK2 cells stably expressing the transcription factor Gal4ERVP for estradiol-inducible transgene expression via pGC vectors (35). In our previous study, we demonstrated that the pGC vector system and the SV40 driven pSVp53her plasmid yield equivalent protein levels (37), thus enabling us to express comparable amounts of PARP-1 and p53her by pGC-PARP and pSVp53her and to induce both protein activities by estradiol. After cotransfection of LMV cells with phyg, which confers hygromycin resistance, and either pSVp53her, pGC-PARP-1 or pSVp53her plus pGC-PARP-1, hygromycin-resistant clones were isolated and screened by western blotting. Ectopic expression of either p53her or PARP-1 was detectable in various clones; however, only one PARP-1 positive clone was successfully established after pSVp53her plus pGC-PARP-1 cotransfection. p53her was constitutively produced and functionally stimulated after estradiol application (LMV-p53her, LMV-p53her/PARP), whereas PARP-1 expression was estradiol-inducible (LMV-PARP, LMV-p53her/PARP) (Fig. 3A,B). LMV-p53her and LMV-PARP cells were characterized by a significant growth retardation, as indicated by a 3- to 4-fold increase in the generation times in the presence of estradiol and a 2-fold increase even in its absence, probably due to residual amounts of estradiol-like substances in the stripped media (Fig. 3B). LMV-p53her/PARP proliferated at extremely retarded growth rates in the absence of estradiol, which again can be explained by basal levels of exogenous PARP-1 and residual p53her activation. Even more strikingly, cultivation in the presence of estradiol resulted in a daily 20% decrease in cell numbers rather than an increase.
###end p 36
###begin p 37
###xml 214 215 214 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c9">9</xref>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c48">48</xref>
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c49">49</xref>
###xml 517 518 515 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f3">3</xref>
###xml 573 574 571 572 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 720 721 706 707 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 980 981 962 963 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1182 1183 1164 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f3">3</xref>
###xml 1589 1591 1571 1573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c26">26</xref>
###xml 1592 1594 1574 1576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c31">31</xref>
###xml 1740 1743 1722 1725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p21</italic>
###xml 1748 1751 1730 1733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bax</italic>
###xml 1779 1780 1761 1762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f3">3</xref>
###xml 1998 1999 1980 1981 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 262 265 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 539 542 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 755 758 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1003 1006 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1018 1021 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1114 1117 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1297 1300 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1369 1372 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1381 1384 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1396 1399 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1543 1546 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1811 1814 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1822 1825 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1968 1981 <span type="species:ncbi:9544">rhesus monkey</span>
PARP-1 has been implicated in induction or execution of apoptosis, although contradictory opinions exist on the underlying mechanism with respect to the involvement of poly(ADP-ribosyl)ation and signalling to p53 (9,48,49). The unusual growth characteristics of LMV-p53her/PARP cells prompted us to analyse these cells for potential apoptotic features. Thus, we performed cell cycle analysis at different times after estradiol exposure by FACS(R) analysis of propidium iodide stained cells. As demonstrated in Figure 3C, the percentage of LMV-p53her/PARP cells with a sub-G1 DNA content, which is strongly indicative of apoptosis, represented approximately10% before and after estradiol treatment. Interestingly, a sub-G1 cell population also appeared in LMV-PARP cells around 48 h (2.5%) of hormone exposure with a further increase until 72 h (8.8%), and similar results were obtained after gamma-irradiation with a dose of 5 Gy (data not shown). Under the same conditions, sub-G1 cells were absent in LMV-p53her and LMV cells. Consistently, when we inspected DAPI stained cell nuclei by fluorescence microscopy, LMV-p53her/PARP cells exhibited typical features of apoptosis (Fig. 3D). Using this method, highly condensed and fragmented nuclei were also found in the samples of estradiol-induced LMV-PARP cells as early as 12 h after irradiation, whereas unirradiated LMV-PARP or LMV-p53her and LMV cell nuclei remained intact. In order to understand whether PARP-1 is a positive regulator of p53-dependent transcriptional transactivation in LMV-p53her/PARP cells under these conditions (26,31), which may be related to the abnormal growth characteristics of these cells, we also investigated the expression of the two major target genes, p21 and Bax, by western blotting (Fig. 3E). As compared with the other LMV lines, LMV-p53her/PARP cells showed dramatically increased levels of p21 and Bax. Our results indicated that PARP-1 expression in cells derived from the rhesus monkey cell line LLC-MK2 is followed by growth retardation and programmed cell death, particularly in a wt-p53-positive background.
###end p 37
###begin title 38
DSB repair in stably transfected cells expressing exogenous PARP-1
###end title 38
###begin p 39
###xml 279 286 275 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EJ-EGFP</italic>
###xml 361 365 357 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 376 378 372 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HR</italic>
###xml 393 397 385 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 433 434 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 435 439 427 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 472 474 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
###xml 632 633 624 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f4">4</xref>
###xml 716 718 708 710 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;2</sup>
###xml 723 730 715 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EJ-EGFP</italic>
###xml 739 741 731 733 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;2</sup>
###xml 746 753 738 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HR-EGFP</italic>
###xml 765 767 757 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;2</sup>
###xml 778 782 766 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 1133 1134 1121 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f1">1</xref>
###xml 1139 1140 1127 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f2">2</xref>
###xml 83 86 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 96 99 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 652 655 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 787 790 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 917 920 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 977 980 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1216 1219 <span type="species:ncbi:12202?0.5">LMV</span>
To investigate whether recombination interference by PARP-1 was also detectable in LMV-PARP and LMV-p53her/PARP cells, we transfected the newly generated stable cell clones with pCMV-I-SceI and either the recombination vector EJ-EGFP/3'EGFP, HR-EGFP/3'EGFP or Delta-EGFP/3'EGFP. EJ-EGFP at the acceptor position additionally supports in frame reconstitution of EGFP via NHEJ, HR- versus Delta-EGFP raises the length of homology with 3'EGFP neighbouring the cleavage site (37). Flow cytometric analysis was performed after 72 h of cultivation in the presence of estradiol and relative recombination frequencies were calculated (Fig. 4). In the parental LMV cells, we measured mean recombination frequencies of 20 x 10-2 for EJ-EGFP, 12 x 10-2 for HR-EGFP and 12 x 10-2 for Delta-EGFP. In LMV-p53her cells, 71-75% of the control values were measured with all three recombination substrates. The relative frequencies in LMV-PARP cells were similarly reduced to 69-81%, whereas in LMV-p53her/PARP cells, we recorded increased rather than decreased mean values (101-138%). Thus, unlike the results after transient PARP-1 expression (Figs 1 and 2), the down-regulatory effect of PARP-1 was abolished in stably transfected LMV-p53her/PARP cells coexpressing p53her.
###end p 39
###begin p 40
###xml 148 149 148 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f3">3</xref>
###xml 376 378 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c50">50</xref>
###xml 802 803 796 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f5">5</xref>
###xml 1124 1125 1118 1119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1275 1276 1269 1270 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1292 1293 1286 1287 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 66 69 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 808 811 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 996 999 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1011 1014 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1058 1061 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1211 1214 <span type="species:ncbi:12202?0.5">LMV</span>
To examine whether the unexpectedly high DSB-repair activities in LMV-p53her/PARP cells were related to the apoptotic features of these cells (Fig. 3C,D), we introduced the recombination plasmid Delta-EGFP/3'EGFP into the same series of cell lines followed by a 24 h treatment with the irreversible caspase 3 inhibitor Z-DEVD-FMK, which also inhibits caspases 6, 7, 8 and 10 (50). FACS(R) analysis of EGFP-positivity was performed after a total cultivation period of 72 h. Importantly, control transfections served to normalize each single recombination frequency, so that we could rule out the possibility that rate deviations were simply caused by altered transfection efficiencies, by growth regulatory effects or differences in cell lethality with the individual cell line used. As shown in Figure 5, in LMV cells no changes in the HR frequencies were detectable in the presence of Z-DEVD-FMK. Similarly, only a minor drug-dependent reduction in the recombination frequencies was measured in LMV-p53her and LMV-PARP cells. However, caspase inhibition in LMV-p53her/PARP cells caused a significant down-regulation of HR (P = 0.036), resulting in the same relative recombination frequency of 78% as seen with LMV-p53her cells. For comparison, Z-DEVD-FMK treatment of LLC-MK2(neo) and LLC-MK2(p53her) cells upon transient transfection with pGC-PARP-1 did not cause a statistically significant reduction in the HR values (data not shown). These findings suggest that apoptotic processes induced by coexpression of PARP-1 and p53her in stably transfected cells may indirectly cause an apparent stimulation of DNA exchange processes that neutralize the anti-recombinogenic activities of PARP-1 and p53her.
###end p 40
###begin title 41
DISCUSSION
###end title 41
###begin p 42
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c8">8</xref>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c33">33</xref>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c51">51</xref>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c52">52</xref>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c55">55</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c34">34</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c38">38</xref>
###xml 703 705 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c11">11</xref>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c20">20</xref>
###xml 1079 1080 1079 1080 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1194 1196 1194 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c56">56</xref>
###xml 1197 1199 1197 1199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c57">57</xref>
Numerous studies have indicated critical roles for both PARP-1 and p53 in the maintenance of genome integrity (reviewed in 8,33,51). PARP-1 and p53 are thought to promote base excision repair (BER) via physical interactions with the BER multiprotein complex (52-55). A large body of evidence also indicates that wt-p53 down-regulates spontaneous and DSB-induced HR (34-38). From our current knowledge, p53 may either block erroneous strand exchange by the recombinase Rad51 or exonucleolytically degrade mispaired intermediates of HR, thereby preventing detrimental rearrangements. However, the molecular mechanism that may underlie the putative anti-recombinogenic role of PARP-1 has remained elusive (11,20). Thus, PARP-1 may directly protect strand breaks from processing or recruit recombination surveillance proteins like WRN or p53. Alternatively, poly(ADP-ribosyl)ation of histones may alter the chromatin configuration and activate p53 functions in HR regulation. From recent reports, poly(ADP-ribosyl)ation may additionally modulate recombination indirectly, because NAD+ depletion inhibits the activity of the Sir2/SIRT1 deacetylase which also affects chromosome remodelling and p53 (56,57).
###end p 42
###begin p 43
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c35">35</xref>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c38">38</xref>
###xml 1128 1130 1128 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c11">11</xref>
###xml 1385 1387 1385 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c10">10</xref>
In the present work, we investigated the role of PARP-1 in DSB repair by use of the rare-cutting, site-specific I-SceI endonuclease, rather than by ionizing irradiation, which introduces base modifications in addition to strand breaks. Therefore, by focusing on targeted DSBs, we were able to exclude indirect effects on HR by DNA excision repair. For our analysis, we utilized two well-established isogenic cellular systems, each with and without wt-p53 (35,37,38). Using two experimental strategies to inactivate PARP-1 enzymatic activity, namely overexpression of PARP-DBD and chemical inhibition, we have observed decreased DSB repair activities in the wt-p53-negative background. Moreover, down- regulation of HR by wt-p53 was further enhanced after PARP-DBD overexpression. Although less markedly, the overexpression of full-length PARP-1 also exerted an inhibitory effect. These results largely excluded an involvement of poly(ADP-ribosyl)ation and p53 signalling in the anti-recombinative effect of PARP-1. Our data rather support the idea that tight binding of PARP-1 to DSBs prevents access for recombination enzymes (11). The less prominent effect by PARP-1 versus PARP-DBD may be explained by the fact that the interaction of PARP-1 with strand breaks is modulated by automodification, i.e. DNA-break sealing will be possible after release of poly(ADP-ribosyl)ated PARP-1 (10).
###end p 43
###begin p 44
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
###xml 605 606 605 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 608 610 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c58">58</xref>
###xml 1112 1113 1100 1101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 1162 1164 1150 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c59">59</xref>
###xml 1250 1253 1238 1241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;10</sup>
###xml 1381 1383 1369 1371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
Our recent studies on the regulatory role of p53 in recombination had indicated an influence of the protein/DNA substrate ratio on the degree of recombination interference (37). In agreement with a similar dose-dependence, the effect of PARP-DBD and PARP-1 on HR was dramatic when the protein/DNA substrate ratio was high in experiments with high-level protein expression and less then 10 intrachromosomally located recombination substrates (37). Conversely, intermediate HR frequency changes were observed with high-level protein expression and extrachromosomal substrates at estimated copy numbers of 105 (58). Moreover, a dose-dependence also became apparent when we studied intrachromosomal HR in the presence of different PARP-DBD and PARP-1 protein levels. Thus, high-level expression of exogenous PARP-DBD or PARP-1 led to a complete suppression of HR as compared with a minor reduction with 100-fold lower protein amounts. High-level expression conditions generated PARP-DBD and PARP-1 levels, which, according to western blot analysis, were similar to endogenous PARP-1, i.e. amounted to approximately106 molecules per cell or one molecule per 1000 bp (59). Importantly, DSB concentrations in the order of the affinity constant of PARP-1 (10-10 M) were achieved in these KMV cells which carried approximately six I-SceI cleavable substrates after chromosomal integration (37). In conclusion, HR suppression by exogenous PARP-DBD and PARP-1 can be explained by direct interactions with DNA breaks.
###end p 44
###begin p 45
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c43">43</xref>
###xml 957 959 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c27">27</xref>
###xml 1150 1152 1150 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c60">60</xref>
###xml 1182 1184 1182 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c61">61</xref>
###xml 1422 1424 1422 1424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c38">38</xref>
###xml 1425 1427 1425 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c39">39</xref>
###xml 1428 1430 1428 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c62">62</xref>
###xml 1431 1433 1431 1433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c64">64</xref>
Interestingly, the small influence of low levels of PARP-DBD and PARP-1 on intrachromosomal recombination was dramatically enhanced in a wt-p53 background. This finding suggested a synergistic effect by p53 and both PARP-DBD and PARP-1, although in experiments with extrachromosomal substrates, the data rather indicated an additive effect. With the DNA-binding domain of PARP-1 being sufficient, this synergism cannot be explained by an involvement of PARP-1 enzymatic activity, thereby excluding p53 activation by poly(ADP-ribosyl)ation, Sir2/SIRT1 inhibition or chromatin opening via charge repulsion by poly(ADP-ribose) chains. The DNA binding domain of PARP-1 was proposed to participate in molecular complexes with proteins involved in genome integrity (43). However with respect to p53, mapping data of the physical interaction site on PARP-1 argue against a synergistic mechanism that would involve physical interactions of p53 within the PARP-DBD (27). Similar to PARP-1 and p53, synergistic activities in minimizing end-to-end fusions and other chromosomal aberrations were also reported for PARP-1 and Ku, another DNA-end binding protein (60), as well as for p53 and Ku (61). p53 has been shown to complex V(D)J recombination intermediates, to specifically recognize early strand exchange intermediates, particularly in trimeric complexes with Rad51, and to abrogate NHEJ and HR involving sequence divergences (38,39,62-64). Therefore, the combined protection of DNA breaks and repair intermediates by PARP-1 and p53 coupled to complementary interactions with repair enzymes of Rad51-independent and -dependent HR pathways may cause a synergistic inhibition particularly in highly organized repair complexes within the nuclear chromatin.
###end p 45
###begin p 46
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c24">24</xref>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c27">27</xref>
###xml 720 722 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c28">28</xref>
###xml 723 725 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c31">31</xref>
###xml 771 772 771 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 814 815 814 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 906 908 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c56">56</xref>
###xml 909 911 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c57">57</xref>
###xml 1621 1623 1621 1623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c50">50</xref>
###xml 1624 1626 1624 1626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c65">65</xref>
###xml 130 133 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 306 309 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 997 1000 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1078 1081 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1206 1209 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1357 1360 <span type="species:ncbi:12202?0.5">LMV</span>
In accord with the results from transient expression studies, HR was down-regulated after PARP-1 expression in stably transfected LMV cells lacking wt-p53. In contrast, in cells stably coexpressing PARP-1 and p53her, indirect effects antagonized HR interference by PARP-1 and wt-p53. Importantly, in these LMV-p53her/PARP cells, a severe reduction in cell survival and a marked transactivation of two p53 target genes were observed in parallel. These results are consistent with two models involving apoptotic signalling of PARP-1 upstream of p53: First, poly(ADP-ribosyl)ation of p53 rapidly enhances accumulation of p53, activation of sequence-specific DNA binding and p53-dependent apoptotic DNA fragmentation (24,27,28,31). Second, prolonged PARP-1 activation and NAD+ depletion may inhibit Sir2/SIRT1, the NAD+-dependent deacetylase which suppresses p53-mediated transactivation and delays apoptosis (56,57). Yet, in the presence of the inducing agent, we also detected apoptotic features in LMV-PARP cells without wt-p53, although to a much lesser degree as compared with LMV-p53her/PARP cells. From this, p53-independent functions of PARP-1 in apoptosis induction may contribute to the phenotype of LMV-p53her/PARP cells. Our recombination experiments performed in the presence of the caspase inhibitor supported the idea that apoptosis induction in LMV-p53her/PARP cells was underlying the failure of exogenous PARP-1 and p53her to down-regulate HR. Previous observations have led to the suggestion that apoptosis positively regulates gene rearrangements; however, the precise mechanism remains to be determined (50,65). One possibility is that the formation of DNA strand breaks which is mediated by apoptotic nucleases may trigger DNA rearrangements.
###end p 46
###begin p 47
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c14">14</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c66">66</xref>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c67">67</xref>
###xml 534 535 534 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c9">9</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c10">10</xref>
###xml 682 684 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c68">68</xref>
###xml 811 813 811 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c12">12</xref>
###xml 995 997 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c69">69</xref>
###xml 1067 1069 1067 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c21">21</xref>
###xml 1070 1072 1070 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c22">22</xref>
###xml 1147 1149 1147 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c23">23</xref>
###xml 1251 1253 1251 1253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c20">20</xref>
Our findings on the anti-recombinogenic role of PARP-1 are consistent with previous reports that documented negative regulation of micronuclei formation, SCEs, chromosome fusions and gene amplification after genotoxic treatment by endogenous and ectopically expressed PARP-1 (14,66,67). They also support the conclusions drawn from double knockout studies indicating a cooperation between p53 and PARP-1 by suppressing chromosome aberrations such as fragmentations, end-to-end fusions and abnormally long and heterogeneous telomeres (9,10). Our data are also in accord with a previous report which demonstrated that resealing of irradiation-induced DSBs is slowed down by PARP-DBD (68). Conversely, in another study PARP-DBD overexpression was shown to enhance gene amplification in response to MNNG treatment (12). At first glance, our data also seem to contradict the results from studies using chemical inhibitors of poly(ADP-ribosyl)ation. Thus, 3-AB stimulated SCEs but not translocations (69), 3-methoxybenzamide potentiated intra- but not extrachromosomal HR (21,22) and 1,5-isoquinolinediol increased the frequency of extrachromosomal HR (23) but did not significantly influence HR on meganuclease-cleaved chromosomally integrated substrates (20). One possible explanation for the different outcomes may be that the known effects of PARP-1 inhibition on DNA base-excision repair and the consequent (indirect) activation of the HR pathway may override to some extent the direct inhibitory effect on HR reported here. Additionally, PARP-1-mediated growth regulation may affect HR measurements as determined by colony formation assays. Taken together, differences in the repair trigger, in the PARP-1/DNA substrate ratio, in the p53-status and cytotoxic effects may have influenced previous studies on the role of PARP-1 in genome stabilization, and this may resolve some of the contradictions. In this work, we largely excluded rate deviations related to indirect effects by targeted DSB formation to trigger HR, by use of a fluorescence-based HR assay with a fast readout and by use of various cellular systems differing in PARP-1 status.
###end p 47
###begin p 48
###xml 231 232 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 572 573 572 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c9">9</xref>
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c10">10</xref>
###xml 621 624 621 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;/&#8211;</sup>
###xml 386 390 <span type="species:ncbi:10090">mice</span>
###xml 625 629 <span type="species:ncbi:10090">mice</span>
In summary, we have established that PARP-1 is a negative regulator of DSB repair in a manner that is dose-dependent and apparently does not involve the covalent modification of target proteins like p53 with poly(ADP-ribose) or NAD+ depletion. The present study further demonstrated cooperative functions of PARP-1 and p53 in suppressing DSB-repair on cellular chromosomes. PARP-1 null mice exhibit high genomic instabilities with a further increase seen in PARP-1 and p53 double knockouts, which are characterized by chromosome aberrations, indicative of deregulated HR (9,10). Moreover, after PARP-1 inactivation in p53-/- mice, tumorigenesis is enhanced and the tumour spectrum widened. Consistently, our results suggest a synergistic role between PARP-1 and p53 in controlling DSB repair processes, thereby synergistically minimizing aberrant chromosomal rearrangements and suppressing tumorigenesis.
###end p 48
###begin title 49
Figures and Tables
###end title 49
###begin p 50
###xml 87 88 87 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 175 179 175 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 209 216 209 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EJ-EGFP</italic>
###xml 217 218 217 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 225 232 225 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HR-EGFP</italic>
###xml 233 234 233 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 235 239 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 249 253 245 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 254 255 250 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 256 260 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 262 264 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
###xml 300 309 296 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">puromycin</italic>
###xml 334 347 330 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">acceptor EGFP</italic>
###xml 505 515 501 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hygromycin</italic>
###xml 544 551 540 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">donor 3</italic>
###xml 552 556 548 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 651 659 647 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">acceptor</italic>
###xml 666 673 662 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EJ-EGFP</italic>
###xml 675 682 671 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HR-EGFP</italic>
###xml 693 697 685 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 785 789 777 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 907 915 899 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">acceptor</italic>
###xml 924 929 916 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">donor</italic>
###xml 1021 1029 1013 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cleavage</italic>
###xml 1041 1049 1033 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink">acceptor</italic>
###xml 1100 1115 1092 1107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gene conversion</italic>
###xml 1118 1121 1110 1113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SSA</italic>
###xml 1123 1133 1115 1125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cross-over</italic>
###xml 1137 1157 1129 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">replication slippage</italic>
###xml 1238 1242 1230 1234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 1255 1263 1247 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">acceptor</italic>
###xml 1508 1512 1500 1504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 1589 1590 1581 1582 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1679 1685 1671 1677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LLC-MK</italic>
###xml 1685 1686 1677 1678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 1685 1686 1677 1678 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>2</italic></sub>
###xml 1686 1691 1678 1683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(neo)</italic>
###xml 1718 1724 1710 1716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LLC-MK</italic>
###xml 1724 1725 1716 1717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 1724 1725 1716 1717 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>2</italic></sub>
###xml 1725 1733 1717 1725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(p53her)</italic>
###xml 1879 1887 1867 1875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARP-DBD</italic>
###xml 1892 1898 1880 1886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARP-1</italic>
###xml 2243 2249 2227 2233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LLC-MK</italic>
###xml 2249 2250 2233 2234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 2249 2250 2233 2234 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>2</italic></sub>
###xml 2250 2255 2234 2239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(neo)</italic>
###xml 2289 2291 2273 2275 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;2</sup>
###xml 2301 2335 2285 2319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">relative recombination frequencies</italic>
###xml 2434 2435 2418 2419 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 2629 2637 2609 2617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARP-DBD</italic>
###xml 2652 2658 2632 2638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARP-1</italic>
###xml 2748 2754 2728 2734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARP-1</italic>
###xml 2783 2791 2763 2771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARP-DBD</italic>
###xml 2861 2866 2841 2846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">actin</italic>
###xml 378 381 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 2693 2697 <span type="species:ncbi:9925">goat</span>
 Effect of PARP-1 and PARP-DBD expression on DSB repair with episomal DNA substrates. (A) Structure of the recombination substrates to assay homology-directed DSB repair. The EGFP-based recombination plasmids EJ-EGFP/3'EGFP, HR-EGFP/3'EGFP or Delta-EGFP/3'EGFP (37) contain the following elements: a puromycin resistance cassette, an acceptor EGFP gene under the control of the CMV promoter and containing a cleavage site (filled triangle) for the rare-cutting I-SceI meganuclease, a spacer region with a hygromycin resistance cassette and the donor 3'EGFP gene, which carries two truncating stop codons in place of the start codon (black cross). The acceptor genes EJ-EGFP, HR-EGFP and Delta-EGFP are characterized by the duplication of 5 bp, or the removal of 4 bp or 46 bp from the EGFP sequence, thereby creating either a sufficient (199 bp, 191 bp) or limiting (164 bp) stretch of homology between the acceptor and the donor genes 5' to the I-SceI recognition sequence. After the expression of I-SceI and subsequent cleavage within the acceptor gene, unilateral transfer of genetic information (gene conversion), SSA, cross-over or replication slippage within the same chromatid or between sister chromatids can restore a functional EGFP gene at the acceptor position. Recombination frequencies were determined as the fraction of green fluorescent cells within the population of nonfluorescent cells. Transfection efficiencies were individually determined in triplicates after electroporation with a wt-EGFP control plasmid and used to normalize each single recombination frequency. (B) Relative recombination frequencies. Recombination assays were performed by lipofecting LLC-MK2(neo) cells devoid of wt-p53 or LLC-MK2(p53her) cells carrying wt-p53 with recombination plasmid Delta-EGFP/3'EGFP and pCMV-I-SceI for I-SceI-mediated substrate cleavage. For overexpression of PARP-DBD and PARP-1, we cotransfected the cells with plasmids pPARP6 and pPARP31, respectively. The control cells received pBS instead. Subsequently, cultivation was continued for 72 h in the presence of estradiol at a final concentration of 1 microM, to fully activate the p53 moiety within the p53her fusion protein. Recombination frequencies in pBS transfected LLC-MK2(neo) cells were taken as 100% (29 x 10-2) and the relative recombination frequencies calculated. The mean values and SEM from three recombination measurements are shown graphically. (C) PARP expression. Western blot analysis of total cellular homogenates was performed 72 h after transfection and cultivation in the presence of 1 microM estradiol with the plasmids pBS, pPARP6 (PARP-DBD) and pPARP31 (PARP-1). For immunodetection, we applied goat polyclonal IgG N-20. The positions of full-length PARP-1 (113 kDa) and the truncated PARP-DBD (38 kDa) are marked by an arrow. The filters were reprobed with anti-actin antibody to control for loading differences.
###end p 50
###begin p 51
###xml 100 101 100 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh227c37">37</xref>
###xml 540 546 540 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pPARP6</italic>
###xml 562 569 562 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pPARP31</italic>
###xml 619 653 619 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">relative recombination frequencies</italic>
###xml 719 721 719 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;4</sup>
###xml 839 840 839 840 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 904 938 904 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Relative recombination frequencies</italic>
###xml 1134 1146 1134 1146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGC-PARP-DBD</italic>
###xml 1150 1160 1150 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGC-PARP-1</italic>
###xml 1478 1479 1475 1476 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 1518 1524 1515 1521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARP-1</italic>
###xml 1529 1537 1526 1534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARP-DBD</italic>
###xml 1628 1640 1625 1637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGC-PARP-DBD</italic>
###xml 1642 1652 1639 1649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGC-PARP-1</italic>
###xml 1659 1666 1656 1663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">control</italic>
###xml 1669 1675 1666 1672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pPARP6</italic>
###xml 1680 1687 1677 1684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pPARP31</italic>
###xml 1701 1702 1698 1699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f1">1</xref>
###xml 1739 1747 1736 1744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARP-DBD</italic>
###xml 1754 1766 1751 1763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGC-PARP-DBD</italic>
###xml 1822 1828 1819 1825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pPARP6</italic>
###xml 1883 1889 1880 1886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARP-1</italic>
###xml 1962 1972 1959 1969 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGC-PARP-1</italic>
###xml 1994 2001 1991 1998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pPARP31</italic>
###xml 2066 2073 2063 2070 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tubulin</italic>
 Effect of PARP-1 and PARP-DBD expression on DSB repair with chromosomal recombination substrates. (A) Homology-directed DSB repair after high-level expression of PARP-DBD and PARP-1. The parental line is the p53-negative line KMV containing the recombination substrate HR-EGFP/3'EGFP in the cellular chromosomes (37). Test cells were subjected to electroporation with pCMV-I-SceI and further cultivated for 48-72 h. For the comparative analysis of PARP-dependent recombination regulatory effects, the cells were coelectroporated with pBS, pPARP6 (PARP-DBD) and pPARP31 (PARP-1), respectively. For the determination of relative recombination frequencies, frequencies in control cells with pBS were taken as 100% (8 x 10-4). Mean values and SEM from two independent experiments with one to three recombination measurements each are shown. (B) DSB repair after low-level expression of PARP-DBD and PARP-1. Relative recombination frequencies were determined from three to six independent measurements after electroporation of KMV and KMV(p53her) cells carrying chromosomally integrated HR-EGFP/3'EGFP with pCMV-I-SceI together with pBS, pGC-PARP-DBD or pGC-PARP-1, and after further cultivation for 72 h in the presence of the inducing agent beta-estradiol (200 nM). Note that estradiol treatment led to transcriptional activation of the pGC-based expression constructs in transfected KMV and KMV(p53her) cells and in addition enabled activation of p53 in KMV(p53her) cells only. (C) Western blot analysis. Expression of PARP-1 and PARP-DBD was analysed after electroporation of KMV cells carrying HR-EGFP/3'EGFP with the plasmids pGC-PARP-DBD, pGC-PARP-1, pBS (control), pPARP6 and pPARP31 as in Figure 1C. Note the weak signal specific for PARP-DBD after pGC-PARP-DBD electroporation as compared with the intense signal in pPARP6 electroporated cells. Correspondingly, an increase in PARP-1 expression above the endogenous expression level was undetectable after pGC-PARP-1 but noticeable after pPARP31 transfection. Equal loading was verified by reprobing with anti-tubulin antibodies.
###end p 51
###begin p 52
###xml 70 71 70 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 160 166 160 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53her</italic>
###xml 201 205 201 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53(</italic>
###xml 210 218 206 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">237&#8211;239)</italic>
###xml 342 348 338 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARP-1</italic>
###xml 420 427 416 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tubulin</italic>
###xml 465 466 461 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 466 476 462 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-p53her</italic>
###xml 478 486 474 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-PARP</italic>
###xml 488 503 484 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-p53her/PARP</italic>
###xml 508 511 504 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV</italic>
###xml 563 569 559 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARP-1</italic>
###xml 644 645 640 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">+</italic>
###xml 650 659 646 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">estradiol</italic>
###xml 795 801 787 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53her</italic>
###xml 812 816 804 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53(</italic>
###xml 821 829 809 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">237&#8211;239)</italic>
###xml 840 846 828 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARP-1</italic>
###xml 861 868 849 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tubulin</italic>
###xml 901 902 882 883 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 939 942 920 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV</italic>
###xml 944 954 925 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-p53her</italic>
###xml 956 964 937 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-PARP</italic>
###xml 969 984 950 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-p53her/PARP</italic>
###xml 1054 1069 1031 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-p53her/PARP</italic>
###xml 1157 1161 1134 1138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n.a.</italic>
###xml 1181 1182 1158 1159 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 1330 1331 1301 1302 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1375 1378 1346 1349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV</italic>
###xml 1380 1390 1351 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-p53her</italic>
###xml 1392 1400 1363 1371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-PARP</italic>
###xml 1405 1420 1376 1391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-p53her/PARP</italic>
###xml 1432 1436 1403 1407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">time</italic>
###xml 1479 1480 1450 1451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 1489 1490 1460 1461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">h</italic>
###xml 1496 1497 1467 1468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">y</italic>
###xml 1545 1546 1516 1517 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1573 1582 1544 1553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">apoptosis</italic>
###xml 1585 1586 1556 1557 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 1649 1652 1620 1623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV</italic>
###xml 1654 1664 1625 1635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-p53her</italic>
###xml 1666 1674 1637 1645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-PARP</italic>
###xml 1679 1694 1650 1665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-p53her/PARP</italic>
###xml 1959 1960 1922 1923 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 1962 1965 1925 1928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p21</italic>
###xml 1970 1973 1933 1936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bax</italic>
###xml 2082 2083 2045 2046 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 2083 2086 2046 2049 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV</italic>
###xml 2088 2098 2051 2061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-p53her</italic>
###xml 2100 2108 2063 2071 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-PARP</italic>
###xml 2113 2128 2076 2091 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-p53her/PARP</italic>
###xml 2209 2212 2172 2175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p21</italic>
###xml 2222 2225 2185 2188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bax</italic>
###xml 2291 2296 2254 2259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">actin</italic>
###xml 262 267 <span type="species:ncbi:9940">sheep</span>
###xml 289 294 <span type="species:ncbi:9606">human</span>
###xml 300 303 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 324 327 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 478 481 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 488 491 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 508 511 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 939 942 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 944 947 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 956 959 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 969 972 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1054 1057 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1375 1378 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1380 1383 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1392 1395 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1405 1408 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1649 1652 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1654 1657 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1666 1669 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 1679 1682 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 2088 2091 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 2100 2103 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 2113 2116 <span type="species:ncbi:12202?0.5">LMV</span>
 Characterization of cell lines stably expressing p53her and PARP-1. (A) Western blot analyses. Immunoblots showing the expression of the ectopically expressed p53her protein and the endogenous mutant p53(Delta237-239), as detected by use of the IgG fraction of sheep serum raised against human p53 (LMV-p53her) or mAb DO1 (LMV-p53her/PARP). PARP-1 was immunodetected by the mAb F-I-23 and the filter reprobed with anti-tubulin antibody. Total homogenates of 2 x 105LMV-p53her, LMV-PARP, LMV-p53her/PARP and LMV control cells were loaded, respectively. Inducible PARP-1 expression was examined after cultivation in the absence (-) or presence (+) of estradiol for 16 h (2 microM). Note that endogenous PARP-1 was hardly detectable at the exposure period chosen. Arrows indicate the positions of p53her (90 kDa), p53(Delta237-239) (53 kDa), PARP-1 (113 kDa) and tubulin (alpha: 57 kDa, beta: 54 kDa). (B) Generation times. Proliferation of LMV, LMV-p53her, LMV-PARP and LMV-p53her/PARP cells was analysed in the absence or presence of 1 microM estradiol. LMV-p53her/PARP cells displayed a 20% reduction in cell number per day when cultivated with estradiol (n.a., not applicable). (C) FACS(R) analyses of propidium iodide stained cells. During a time course of 72 h after estradiol application (1 microM), the appearance of a sub-G1 peak was followed flow- cytometrically for LMV, LMV-p53her, LMV-PARP and LMV-p53her/PARP cells. The time after estradiol induction is given at the x-axis in h, the y-axis shows the percentage of cells with a sub-G1 DNA content indicative of apoptosis. (D) Microscopic detection of apoptotic features. After culturing LMV, LMV-p53her, LMV-PARP and LMV-p53her/PARP for 4 h in estradiol-containing medium (1 microM), the cells were treated with a single dose of 5 Gy and cultivation continued for 12 h followed by staining with DAPI and fluorescence microscopy. Arrows denote apoptotic cell nuclei. The bar represents 50 microm. (E) p21 and Bax expression. Cells were estradiol-induced and irradiated as in (D). Subsequently, total homogenates of 3 x 105LMV, LMV-p53her, LMV-PARP and LMV-p53her/PARP cells were subjected to western blotting and immunodetection by use of the anti-p21 and anti-Bax mAbs Ab-1 and 2D2, respectively, followed by reprobing with anti-actin antibody.
###end p 52
###begin p 53
###xml 122 129 122 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EJ-EGFP</italic>
###xml 131 138 131 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HR-EGFP</italic>
###xml 148 152 144 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 157 158 153 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 159 163 155 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 212 228 208 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53her, &#8211; PARP-1</italic>
###xml 243 261 239 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">+ p53her, &#8211; PARP-1</italic>
###xml 276 292 272 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53her, + PARP-1</italic>
###xml 321 339 317 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">+ p53her, + PARP-1</italic>
###xml 470 504 466 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">relative recombination frequencies</italic>
###xml 671 673 667 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;2</sup>
###xml 678 685 674 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EJ-EGFP</italic>
###xml 694 696 690 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;2</sup>
###xml 701 708 697 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HR-EGFP</italic>
###xml 717 719 713 715 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;2</sup>
###xml 730 734 722 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFP</italic>
###xml 26 29 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 38 41 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 51 54 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 205 208 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 231 234 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 264 267 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 298 301 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 645 648 <span type="species:ncbi:12202?0.5">LMV</span>
 Homologous DSB repair in LMV-p53her, LMV-PARP and LMV-p53her/PARP cells. Homologous exchange was analysed between either EJ-EGFP, HR-EGFP or Delta-EGFP and 3'EGFP (upper panel map) after colipofection of LMV (- p53her, - PARP-1), LMV-p53her (+ p53her, - PARP-1), LMV-PARP (- p53her, + PARP-1) and LMV-p53her/PARP cells (+ p53her, + PARP-1) with the respective recombination construct and the meganuclease expression vector pCMV-I-SceI. Mean values including SEM of the relative recombination frequencies are diagrammatically shown for two to six independent experiments with two or three measurements each. The recombination frequencies in the LMV control cells (20 x 10-2 for EJ-EGFP, 12 x 10-2 for HR-EGFP, 12 x 10-2 for Delta-EGFP) were taken as 100%.
###end p 53
###begin p 54
###xml 111 145 111 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">relative recombination frequencies</italic>
###xml 194 195 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh227f4">4</xref>
###xml 285 288 281 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV</italic>
###xml 292 308 288 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53her, &#8211; PARP-1</italic>
###xml 311 321 307 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-p53her</italic>
###xml 323 341 319 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">+ p53her, &#8211; PARP-1</italic>
###xml 344 352 340 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-PARP</italic>
###xml 356 372 352 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53her, + PARP-1</italic>
###xml 378 393 374 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMV-p53her/PARP</italic>
###xml 395 413 391 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">+ p53her, + PARP-1</italic>
###xml 444 455 440 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">filled bars</italic>
###xml 489 498 485 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">open bars</italic>
###xml 42 45 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 285 288 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 311 314 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 344 347 <span type="species:ncbi:12202?0.5">LMV</span>
###xml 378 381 <span type="species:ncbi:12202?0.5">LMV</span>
 Caspase inhibition affects DSB repair in LMV-p53her/PARP cells. Homology-directed DSB repair was analysed and relative recombination frequencies calculated as described in the legend to Figure 4. After lipofection with the recombination plasmid Delta-EGFP/3'EGFP and with pCMV-I-SceI LMV (- p53her, - PARP-1), LMV-p53her (+ p53her, - PARP-1), LMV-PARP (- p53her, + PARP-1) and LMV-p53her/PARP (+ p53her, + PARP-1), cells were treated without (filled bars) and with the caspase inhibitor (open bars) for 24 h.
###end p 54
###begin title 55
ACKNOWLEDGEMENTS
###end title 55
###begin p 56
Our special thanks go to Nuray Akyuz for introduction to FACS(R) analysis. We thank Prof. G.G. Poirier, Quebec, Canada, for antibody F-I-23, Marion Kurth for initial help and Evelyn Bendrat for experimental assistance during clonal establishment. This work was supported by the Deutsche Forschungsgemeinschaft, grants Wi 1376/1-5 and Wi 1376/3-1 and by the Land Baden-Wurttemberg, Forschungs schwerpunktprogramm: Fehlregulation von Apoptose als Grundlage fur Krankheit.
###end p 56
###begin title 57
REFERENCES
###end title 57

